Unknown

Dataset Information

0

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status

ABSTRACT:

SUBMITTER: Bittner M 

PROVIDER: S-EPMC12940316 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.
| S-EPMC5884655 | biostudies-literature
Unknown NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
| S-EPMC9716250 | biostudies-literature
Unknown Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a <i>KRAS</i>-mutated low-grade serous ovarian cancer patient.
| S-EPMC6913142 | biostudies-literature
Unknown The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
| S-EPMC10359414 | biostudies-literature
Unknown Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
| S-EPMC5088288 | biostudies-literature
Unknown Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
| S-EPMC8557133 | biostudies-literature
Unknown Prognostic Relevance of Clinical and Tumor Mutational Profile in High-Grade Serous Ovarian Cancer
| S-EPMC12347516 | biostudies-literature
Unknown Differential expression of immune related genes in high-grade ovarian serous carcinoma.
| S-EPMC7396156 | biostudies-literature
Unknown KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
| S-EPMC8018312 | biostudies-literature
Unknown Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
| S-EPMC4959443 | biostudies-literature